Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1918
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends ; volume:42 ; number:8 ; day:13 ; month:7 ; year:2022 ; pages:631-642 ; date:8.2022
Clinical drug investigation ; 42, Heft 8 (13.7.2022), 631-642, 8.2022
- Urheber
-
Figueiredo, Arnaldo
Costa, Luís
Maurício, Maria Joaquina
Figueira, Luís
Ramos, Rodrigo
Martins-da-Silva, Carlos
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-022-01178-y
- URN
-
urn:nbn:de:101:1-2022101517043271868510
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Figueiredo, Arnaldo
- Costa, Luís
- Maurício, Maria Joaquina
- Figueira, Luís
- Ramos, Rodrigo
- Martins-da-Silva, Carlos
- SpringerLink (Online service)
Ähnliche Objekte (12)
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Effect of simvastatin on castration-resistant prostate cancer cells
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Effect of simvastatin on castration-resistant prostate cancer cells
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan